文献速递冠心病心力衰竭与心肌病

沙库巴曲缬沙坦对急性心肌梗死后主要冠脉事件的影响:PARADISE-MI 试验分析

The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
PubMed 文献 · Circulation · 2022-11-02

PARADISE-MI 试验预设分析,纳入 5661 例急性心肌梗死合并左室收缩功能不全和/或肺淤血患者,比较沙库巴曲缬沙坦与雷米普利对冠脉复合结局的影响。中位随访 22 个月,沙库巴曲缬沙坦降低冠脉复合结局风险(HR 0.86,95%CI 0.74-0.99,P=0.04)。

要点

  • 急性心梗后高危患者中,沙库巴曲缬沙坦较雷米普利降低预设冠脉复合结局风险。
  • 复合结局各组分发生率在沙库巴曲缬沙坦组较低,但单独均未达显著差异。
  • 该分析为预设探索性分析,结论需专门研究确认。

核心结论

  • 在急性心肌梗死合并左室收缩功能不全和/或肺淤血的患者中,沙库巴曲缬沙坦较雷米普利降低预设主要冠脉复合结局风险。

研究设计与样本

  • PARADISE-MI 试验的预设分析,纳入 5661 例急性心肌梗死合并左室收缩功能不全、肺淤血或两者兼有的患者。
  • 患者随机接受沙库巴曲缬沙坦 97/103 mg 每日两次或雷米普利 5 mg 每日两次。
  • 随机化距指数心梗中位 4.4(3.0-5.8)天,89% 患者已接受冠脉再灌注。

主要发现

  • 中位随访 22 个月,沙库巴曲缬沙坦较雷米普利降低冠脉复合结局风险(HR 0.86,95%CI 0.74-0.99,P=0.04)。
  • 复合结局各组分发生率在沙库巴曲缬沙坦组较低,但单独均未达显著差异。

关键数值与推荐

  • 预设冠脉复合结局定义为冠心病死亡、非致死性心肌梗死、因心绞痛住院或随机化后冠脉血运重建的首次发生。
  • 指数心梗类型:ST 段抬高型心肌梗死 76%,非 ST 段抬高型心肌梗死 24%。

临床怎么用

  • 对于急性心肌梗死后合并左室收缩功能不全和/或肺淤血的高危患者,沙库巴曲缬沙坦可能较雷米普利进一步降低主要冠脉事件风险。

局限性

  • 该分析为预设分析,冠脉复合结局各组分单独未达显著差异,结论需专门研究确认并阐明机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients who survive an acute myocardial infarction (AMI), angiotensin-converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events. Whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan reduce major coronary events more effectively than angiotensin-converting enzyme inhibitors in high-risk patients with recent AMI remains unknown. We aimed to compare the effects of sacubitril/valsartan on coronary outcomes in patients with AMI. METHODS: We conducted a prespecified analysis of the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitors Trial to Determine Superiority in Reducing Heart Failure Events After MI), which compared sacubitril/valsartan (97/103 mg twice daily) with ramipril (5 mg twice daily) for reducing heart failure events after myocardial infarction in 5661 patients with AMI complicated by left ventricular systolic dysfunction, pulmonary congestion, or both. In the present analysis, the prespecified composite coronary outcome was the first occurrence of death from coronary heart disease, nonfatal myocardial infarction, hospitalization for angina, or postrandomization coronary revascularization. RESULTS: Patients were randomly assigned at a median of 4.4 [3.0-5.8] days after index AMI (ST-segment-elevation myocardial infarction 76%, non-ST-segment-elevation myocardial infarction 24%), by which time 89% of patients had undergone coronary reperfusion. Compared with ramipril, sacubitril/valsartan decreased the risk of coronary outcomes (hazard ratio, 0.86 [95% CI, 0.74-0.99], P=0.04) over a median follow-up of 22 months. Rates of the components of the composite outcomes were lower in patients on sacubitril/valsartan but were not individually significantly different. CONCLUSIONS: In survivors of an AMI with left ventricular systolic dysfunction and pulmonary congestion, sacubitril/valsartan-compared with ramipril-reduced the risk of a prespecified major coronary composite outcome. Dedicated studies are necessary to confirm this finding and elucidate its mechanism. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02924727.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Mehran, Steg, Pfeffer, et al. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation. 2022. PMID: 36321459. doi:10.1161/CIRCULATIONAHA.122.060841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。